Eton Pharmaceuticals Expands Rare Disease Portfolio with IMPAVIDO® Commercialization Rights

summarizeSummary

Eton Pharmaceuticals has acquired U.S. commercialization rights for IMPAVIDO®, an FDA-approved Orphan Drug for leishmaniasis, further expanding its rare disease product portfolio.

check_boxKey Events

• Acquisition of Commercialization Rights

  Eton Pharmaceuticals entered into a supply and distribution agreement for the exclusive U.S. commercialization rights to IMPAVIDO® (miltefosine) oral capsules, an FDA-approved Orphan Drug for leishmaniasis.

• Financial Terms Detailed

  The agreement includes $4.25 million in fixed fees paid through March 2032, up to $4.0 million in sales-based milestone payments, and a revenue split of 55% of net sales up to $7.0 million annually, and 50% above that threshold.

• Strategic Portfolio Expansion

  This transaction further expands Eton's growing portfolio of orphan therapies, aligning with the company's focus on specialized patient populations and building on recent product launches and acquisitions.

• Established Product with Existing Sales

  IMPAVIDO® recorded U.S. sales of $8.1 million in 2025, providing an immediate revenue stream for Eton when its exclusive commercialization rights begin on September 26, 2026.

auto_awesomeAnalysis

Eton Pharmaceuticals is strategically expanding its rare disease portfolio by securing U.S. commercialization rights for IMPAVIDO®, an FDA-approved Orphan Drug with established sales. This move builds on the company's recent positive momentum, including new product approvals and strong financial performance, and is expected to contribute to future revenue growth in a specialized market segment. This agreement comes as the stock trades near its 52-week high, reinforcing positive investor sentiment.